Trial Profile
GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Pixantrone (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms GOAL
- 01 Aug 2022 Primary endpoint has not been met (Objective overall response rate after six treatment cycles or the individual end of treatment) , according to Results published in the British Journal of Haematology
- 01 Aug 2022 Final results published in the British Journal of Haematology
- 30 Mar 2022 Status changed from active, no longer recruiting to completed.